实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2015年
2期
295-297,300
,共4页
沙利度胺%多发性骨髓瘤%疗效%血清指标
沙利度胺%多髮性骨髓瘤%療效%血清指標
사리도알%다발성골수류%료효%혈청지표
Thalidomide%Multiple myeloma tumor%Efficacy%Serum indicators
目的：探讨沙利度胺治疗多发性骨髓瘤的疗效及其对血清相关指标的影响。方法将90例多发性骨髓肿瘤患者按照入院顺序随机分为2组，各45例。对照组患者接受VAD方案化疗，观察组患者则采用沙利度胺联合VAD方案，比较2组间疗效差异以及疾病相关指标差异。结果2组患者间疗效等级比较，差异有统计学意义；观察组总有效率为75．56％，显著高于对照组的51．11％（ P＜0．05）。治疗后第8、16周，观察组患者血清β2-MG、M蛋白水平及骨髓浆细胞含量、ESR显著低于对照组，血红蛋白含量显著高于对照组；观察组CRP、IL-6、TNF-α和 sFas水平显著低于对照组，IL-33水平显著高于对照组，P＜0．05。结论沙利度胺能调节MM疾病相关因子的表达，改善MM疾病指标，与VAD方案联用时能提高疗效。
目的：探討沙利度胺治療多髮性骨髓瘤的療效及其對血清相關指標的影響。方法將90例多髮性骨髓腫瘤患者按照入院順序隨機分為2組，各45例。對照組患者接受VAD方案化療，觀察組患者則採用沙利度胺聯閤VAD方案，比較2組間療效差異以及疾病相關指標差異。結果2組患者間療效等級比較，差異有統計學意義；觀察組總有效率為75．56％，顯著高于對照組的51．11％（ P＜0．05）。治療後第8、16週，觀察組患者血清β2-MG、M蛋白水平及骨髓漿細胞含量、ESR顯著低于對照組，血紅蛋白含量顯著高于對照組；觀察組CRP、IL-6、TNF-α和 sFas水平顯著低于對照組，IL-33水平顯著高于對照組，P＜0．05。結論沙利度胺能調節MM疾病相關因子的錶達，改善MM疾病指標，與VAD方案聯用時能提高療效。
목적：탐토사리도알치료다발성골수류적료효급기대혈청상관지표적영향。방법장90례다발성골수종류환자안조입원순서수궤분위2조，각45례。대조조환자접수VAD방안화료，관찰조환자칙채용사리도알연합VAD방안，비교2조간료효차이이급질병상관지표차이。결과2조환자간료효등급비교，차이유통계학의의；관찰조총유효솔위75．56％，현저고우대조조적51．11％（ P＜0．05）。치료후제8、16주，관찰조환자혈청β2-MG、M단백수평급골수장세포함량、ESR현저저우대조조，혈홍단백함량현저고우대조조；관찰조CRP、IL-6、TNF-α화 sFas수평현저저우대조조，IL-33수평현저고우대조조，P＜0．05。결론사리도알능조절MM질병상관인자적표체，개선MM질병지표，여VAD방안련용시능제고료효。
Objective To observe the efficacy of thalidomide for patients with multiple myeloma tumor( MM) and its in-fluence on related serum indicators.Methods 90 patients with multiple myeloma tumor were randomly divided into the control group and the observation group,each group had 45 cases.The control group received VAD chemotherapy,and the observation group received VAD chemotherapy combined with thalidomide.Then the differences of efficacy and diseases related indicators be-tween the 2 groups were compared.Results There was significant difference in the efficacy rating between the 2 groups of pa-tients,the total effective rate of the observation group was 75.56% which was significantly higher than 51.11% in the control group.After 8,16 weeks of treatment,the serum levels ofβ2-MG,M protein,the bone marrow plasma cell content and ESR of the observation group were lower than those of the control group, while the hemoglobin content was higher than that of the control group;and the serum levels of CRP,IL-6,TNF-αand sFas of the observation group were lower than those of the control group,but the level of IL-33 was higher than that of the control group,all P<0.05.Conclusion Thalidomide can effectively regulate the expression of MM disease-related factors,improve MM disease indicators,and can improve efficacy when combined with VAD pro-gram.
